王宏建

【摘要】 目的：观察儿童型双黄连口服液联合阿奇霉素治疗小儿支原体肺炎的临床效果。方法：选取2015年1月-2016年4月在笔者所在医院治疗的110例支原体肺炎患儿，随机分为观察组和对照组各55例，对照组患儿采取常规对症处理加阿奇霉素治疗，观察组在对照组基础上联合儿童型双黄连口服液治疗，对两组患儿的临床疗效和临床症状改善情况进行评价，比较两组患儿临床效果。结果：疗程结束后，观察组临床总有效率分别为92.7%，高于对照组的78.2%，比较差异有统计学意义（P<0.05）；观察组患儿退热时间、咳嗽消失时间、肺部啰音消失时间均短于对照组，比较差异均有统计学意义（P<0.05）。结论：儿童型双黄连口服液用于治疗小儿支原体肺炎疗效显著，口感清甜，儿童易于接受，且有明确的不同年龄段儿童的用法用量，值得在临床上广泛推广应用。

【关键词】 阿奇霉素； 支原体肺炎； 儿童型双黄连口服液

doi：10.14033/j.cnki.cfmr.2018.7.011 文献标识码 B 文章编号 1674-6805（2018）07-0025-03

【Abstract】 Objective：To observe the clinical effect of Shuanghuanglian Oral Liquid （Only for Children）combined with Azithromycin in the treatment of mycoplasmal pneumonia in children.Method：From January 2015 to April 2016，a total of 110 children with mycoplasma pneumonia were enrolled in our hospital and were randomly divided into observation group and control group.The control group were treated with Azithromycin，and the observation group was treated with Shuanghuanglian Oral Liquid on the basis of the control group.The clinical efficacy and clinical symptom improvement of two groups of children were evaluated，and the clinical effect was compared between the two groups.Result：After treatment，the total effective rate in the observation group was 92.7%，which was higher than that in the control group（78.2%），the difference was statistically significant（P<0.05）.The antipyretic time，cough disappear time，pulmonary rales disappear time of the observation group were shorter than those of the control group，the differences were statistically significant（P<0.05）.Conclusion：Shuanghuanglian Oral Liquid for the treatment of mycoplasma pneumonia in children significant effect，taste sweet，easy to be accepted by children，and has clear usage and dosage of children of different ages，it is widely used in clinical practice.

【Key words】 Azithromycin； Mycoplasma pneumonia； Shuanghuanglian oral liquid for children

First-authors address：Pingyi County Maternal and Children Health Care Hospital，Pingyi 273300，China

支原體肺炎是儿童常见疾病，临床表现主要为发热、咳嗽、喘息等，主要病原为肺炎支原体，支原体感染属非典型微生物感染，其在社区获得性呼吸道感染及儿童肺炎中均占重要的病原学地位[1]。肺炎支原体主要通过飞沫传播，一年四季均可发生，其发病的情况随季节、性别、年龄、地区的不同而有差异[2]。肺炎支原体是迄今能在无生命培养基中生长繁殖的最小的原核细胞微生物，是介于细菌与病毒之间的无细胞壁微生物，故内酰胺类抗生素（作用于细胞壁）对其不起作用，因此临床上使用大环内酯类抗生素（作用于蛋白质）治疗。但抗生素的广泛使用也加快了细菌变异，产生耐药性，因此当前临床使用第二代大环内酯类药物阿奇霉素。尽管耐药性降低，但治疗周期较长，易出现不良反应[3]。儿童型双黄连口服液在抗菌方面有耐药性低、不良反应少的优势，故笔者所在医院用其治疗支原体肺炎患儿，疗效显著，现总结报道如下。……